Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Retina. 2019 May;39(5):948–955. doi: 10.1097/IAE.0000000000002044

Figure 5.

Figure 5

A case of pseudophakic cystoid macular edema (#14L) unresponsive to topical 1% prednisolone acetate (PA), intravitreal triamcinolone (IVTA), and twelve prior intravitreal bevacizumab injections, that responded to acetazolamide 500 mg twice daily, and resolved completely with the addition of 0.05% difluprednate 4×/day. Resolution was maintained with acetazolamide plus 0.5% loteprednol etabonate. Recurrence occurred rapidly after discontinuation of acetazolamide (side effects) despite continued topical loteprednol. Edema resolved again with the addition of methazolamide 50 mg twice daily. This regimen maintained resolution for over three years. VA: visual acuity. CST: central macular subfield thickness.